The present invention relates to a method for diagnosing peritoneal carcinoses or metastatic primary tumors in a subject, as well as to a method for providing a prognosis to a subject diagnosed with a primary tumor to develop metastases, in particular peritoneal carcinosis, comprising the step of determining the level of expression of at least phosphoglycerate kinase 1 (PGK1) gene. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the activity and/or expression of phosphoglycerate kinase 1 (PGK1) and/or β-catenin, either alone or in combination with the detection of CXCR4 and/or CXCL12, for the diagnosis or prognosis of peritoneal carcinoses and/or metastatic primary tumors. Also, a method for the preventive treatment of peritoneal carcinoses and/or metastatic primary tumors in a subject in need thereof is disclosed, wherein the method comprises the step of administering to the subject at least a pharmaceutically effective amount of a substance inhibiting the activity and/or expression of phosphoglycerate kinase 1 (PGK1).
